Outlook Therapeutics Inc
OTLK2.010USD
-0.060-2.90%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
87.39MMarket Cap
LossP/E TTM
More Details of Outlook Therapeutics Inc Company
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Outlook Therapeutics Inc Info
Ticker SymbolOTLK
Company nameOutlook Therapeutics Inc
IPO dateJun 13, 2016
CEOJahr (Robert Charles)
Number of employees23
Security typeOrdinary Share
Fiscal year-endJun 13
Address111 S. Wood Avenue
CityISELIN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08830
Phone16096193990
Websitehttps://outlooktherapeutics.com/
Ticker SymbolOTLK
IPO dateJun 13, 2016
CEOJahr (Robert Charles)
Company Executives of Outlook Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Mr. Julian S. Gangolli
Mr. Julian S. Gangolli
Independent Director
Independent Director
--
--
Prof. Dr. Gerd Auffarth, M.D.
Prof. Dr. Gerd Auffarth, M.D.
Independent Director
Independent Director
--
--
Mr. Andong Huang
Mr. Andong Huang
Independent Director
Independent Director
--
--
Mr. Ralph H. (Randy) Thurman
Mr. Ralph H. (Randy) Thurman
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Kurt J. Hilzinger
Mr. Kurt J. Hilzinger
Independent Director
Independent Director
23.66K
--
Mr. Faisal Ghiath Sukhtian
Mr. Faisal Ghiath Sukhtian
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
--
Mr. Yezan Munther Haddadin
Mr. Yezan Munther Haddadin
Independent Director
Independent Director
3.17K
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Lawrence A. (Larry) Kenyon
Mr. Lawrence A. (Larry) Kenyon
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
--
--
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GMS Ventures and Investments
21.14%
Syntone Ventures LLC
2.66%
The Vanguard Group, Inc.
2.09%
Schonfeld Strategic Advisors LLC
1.12%
BlackRock Institutional Trust Company, N.A.
0.57%
Other
72.42%
Shareholders
Shareholders
Proportion
GMS Ventures and Investments
21.14%
Syntone Ventures LLC
2.66%
The Vanguard Group, Inc.
2.09%
Schonfeld Strategic Advisors LLC
1.12%
BlackRock Institutional Trust Company, N.A.
0.57%
Other
72.42%
Shareholder Types
Shareholders
Proportion
Corporation
23.80%
Investment Advisor
3.49%
Hedge Fund
1.54%
Investment Advisor/Hedge Fund
0.72%
Research Firm
0.50%
Individual Investor
0.12%
Bank and Trust
0.08%
Venture Capital
0.02%
Other
69.74%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
193
6.11M
13.76%
-8.94M
2025Q2
200
23.11M
54.78%
+2.16M
2025Q1
206
18.99M
51.79%
+1.54M
2024Q4
199
13.00M
49.47%
-2.41M
2024Q3
196
16.85M
70.81%
+1.73M
2024Q2
189
16.98M
71.93%
+3.50M
2024Q1
185
15.51M
74.39%
+7.93M
2023Q4
178
7.21M
55.91%
-348.31K
2023Q3
180
7.28M
56.56%
-251.17K
2023Q2
176
8.12M
63.26%
-296.08K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GMS Ventures and Investments
13.55M
30.51%
+4.29M
+46.25%
May 27, 2025
Syntone Ventures LLC
1.71M
3.84%
+714.29K
+72.07%
Apr 17, 2024
The Vanguard Group, Inc.
1.25M
2.82%
+414.19K
+49.46%
Jun 30, 2025
Schonfeld Strategic Advisors LLC
1.36M
3.07%
-187.94K
-12.10%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
330.26K
0.74%
-846.69K
-71.94%
Jun 30, 2025
Geode Capital Management, L.L.C.
265.63K
0.6%
-168.22K
-38.77%
Jun 30, 2025
Susquehanna International Group, LLP
117.77K
0.27%
+46.85K
+66.05%
Jun 30, 2025
Millennium Management LLC
338.57K
0.76%
+338.57K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 3000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Date
Type
Ratio
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
Mar 12, 2024
Merger
20→1
FAQs
Who are the top five shareholders of Outlook Therapeutics Inc?
The top five shareholders of Outlook Therapeutics Inc are:
GMS Ventures and Investments holds 13.55M shares, accounting for 30.51% of the total shares.
Syntone Ventures LLC holds 1.71M shares, accounting for 3.84% of the total shares.
The Vanguard Group, Inc. holds 1.25M shares, accounting for 2.82% of the total shares.
Schonfeld Strategic Advisors LLC holds 1.36M shares, accounting for 3.07% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 330.26K shares, accounting for 0.74% of the total shares.
GMS Ventures and Investments holds 13.55M shares, accounting for 30.51% of the total shares.
Syntone Ventures LLC holds 1.71M shares, accounting for 3.84% of the total shares.
The Vanguard Group, Inc. holds 1.25M shares, accounting for 2.82% of the total shares.
Schonfeld Strategic Advisors LLC holds 1.36M shares, accounting for 3.07% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 330.26K shares, accounting for 0.74% of the total shares.
What are the top three shareholder types of Outlook Therapeutics Inc?
The top three shareholder types of Outlook Therapeutics Inc are:
GMS Ventures and Investments
Syntone Ventures LLC
The Vanguard Group, Inc.
GMS Ventures and Investments
Syntone Ventures LLC
The Vanguard Group, Inc.
How many institutions hold shares of Outlook Therapeutics Inc (OTLK)?
As of 2025Q3, 193 institutions hold shares of Outlook Therapeutics Inc, with a combined market value of approximately 6.11M, accounting for 13.76% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -41.02%.
What is the biggest source of revenue for Outlook Therapeutics Inc?
In --, the -- business generated the highest revenue for Outlook Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
